Fig. 3.
Fig. 3. Histograms showing (A) the number and (B) the area of osteolytic lesions in the lumbar vertebrae of 5TGM1 myeloma-bearing and control mice with and without ibandronate treatment (4 μg per mouse per day for 28 days). Lesions were quantified by computerized image analysis from radiographs taken at sacrifice. Data are mean ± SEM (n = 6). ∗, Significant reduction compared with myeloma + PBS. (C) Histogram showing the effect of ibandronate treatment (4 μg per mouse per day for 28 days) on the mean height of the lumbar vertebrae in 5TGM1 myeloma-bearing and control mice. The height of each lumbar vertebra was measured by image analysis from radiographs taken at sacrifice and the mean vertebral height calculated for each animal. Data are mean ± SEM (n = 6). +, Significant decrease compared with PBS treated non–tumor-bearing control. ∗, Significant increase compared with myeloma + PBS.

Histograms showing (A) the number and (B) the area of osteolytic lesions in the lumbar vertebrae of 5TGM1 myeloma-bearing and control mice with and without ibandronate treatment (4 μg per mouse per day for 28 days). Lesions were quantified by computerized image analysis from radiographs taken at sacrifice. Data are mean ± SEM (n = 6). ∗, Significant reduction compared with myeloma + PBS. (C) Histogram showing the effect of ibandronate treatment (4 μg per mouse per day for 28 days) on the mean height of the lumbar vertebrae in 5TGM1 myeloma-bearing and control mice. The height of each lumbar vertebra was measured by image analysis from radiographs taken at sacrifice and the mean vertebral height calculated for each animal. Data are mean ± SEM (n = 6). +, Significant decrease compared with PBS treated non–tumor-bearing control. ∗, Significant increase compared with myeloma + PBS.

Close Modal

or Create an Account

Close Modal
Close Modal